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We report a novel 14724G>A mutation in the mitochondrial tRNA glutamic acid gene in a 4-year-old boy with myopathy and leu-
koencephalopathy. A muscle biopsy showed cytochrome c oxidase-negative ragged-red ﬁbers and biochemical analysis of the respiratory
chain enzymes in muscle homogenate revealed partial complex I and complex IV deﬁciencies. The mutation, which aﬀects the dihydro-
uridine arm at a conserved site, was nearly homoplasmic in muscle and heteroplasmic in blood DNA of the proband, but it was absent in
peripheral leukocytes from the asymptomatic mother, sister, and two maternal aunts, suggesting that it arose de novo. This report pro-
poses to look for variants in the mitochondrial genome when dealing with otherwise undetermined leukodystrophies of childhood.
 2007 Elsevier Inc. All rights reserved.
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neous group of disorders of oxidative phosphorylation
(OXPHOS) in which patients exhibit symptoms starting
at any age and often include neurological and muscular
dysfunctions that can be complicated with cardiac, renal,
hepatic, or endocrine involvements [1,2]. The spectrum of
brain disorders is highly pleiomorphic and includes
symptoms aﬀecting the cortical and subcortical struc-
tures, and the white matter. In this respect, astrocyte or
oligodendocyte functions are highly dependent upon
ATP production through the OXPHOS [3] and so might0006-291X/$ - see front matter  2007 Elsevier Inc. All rights reserved.
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inho@igm.min-saude.pt (L. Vilarinho).presumably be their interactions with neurons. There-
fore, it is no surprise if mtDNA variants are recognized
as causative in otherwise undetermined leukodystrophies
(UL) [4–6].
For the synthesis of its proteins, mitochondria are
dependent on the nuclear and mitochondrial genomes that
operate a twin control on the complex assembly machinery
[7,8]. Of the almost 200 pathogenic mtDNA mutations
reported to date [2], www.mitomap.org, about 75% are in
the 22 mitochondrial transfer RNA (mt-tRNA) genes,
although their sequences represent only a small part of
the mitochondrial chromosome. We identiﬁed a child car-
rying a diagnosis of UL in whom we detected a novel muta-
tion in the tRNAGlu gene. The molecular consequences of
this new variant were studied in skeletal muscle using
immunohistochemical, spectrophotometric, and single-
muscle ﬁber techniques.
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This 4-year-old-boy, the ﬁrst child born to healthy, unrelated par-
ents achieved the normal developmental milestones until he showed
unsteady gate and hypotonia at age 3 months. A brain MRI showed the
presence of periventricular white matter hyperluciencies along with
basal ganglia calciﬁcations (Fig. 1a). Careful clinical and neurophysi-
ological examinations revealed a hypotonia, macrocephaly, and cere-
bellar ataxia at age 1 year. Serum lactate level was elevated (3.60 mmol/
L, normal: 0.63–2.44) but lactate/pyruvate ratio was normal. Family
history was unremarkable for neurological and neuromuscular disor-
ders. The 2-year-old sister is asymptomatic.
A skeletal muscle biopsy specimen was taken at age 2.5 years
and analyzed for abnormal mitochondrial function using standard
morphological methodologies, as well as spectrophotometric mea-
surement of respiratory chain complexes and citrate synthase [9,10].
Total DNA was extracted from muscle and peripheral blood and
the most commonly encountered mtDNA point mutations where
looked for by established diagnostic, PCR-based strategies, as
reported elsewhere [11,12]. Direct sequencing of the whole mito-
chondrial genome, including the 22 mt-tRNAs was performed on an
ABI 310 (Applied Biosystems). Quantiﬁcation of mutant mtDNA
used a mispairing PCR method and employed the endonuclease
RsaI. Single muscle ﬁbers were selected, isolated, and analyzed by
PCR using a modiﬁcation of the laser capture microdissection
(LCM-PCR) technique which allows the selective sampling of tissue
from histological sections [13,14]. The aforementioned PCR- RFLP
strategy allowed us to quantify levels of mutant mtDNAs in single
myocytes.
Comparison of quantitative parameters between groups was per-
formed using the Mann–Whitney test. A p value below 0.05 was consid-
ered signiﬁcant.Fig. 1. (a) Brain MRI in a child harboring the novel 14724G>A mutation. Ax
hyperlucencies. (b) Morphological investigations in muscle sections: Gomori tr
oxidase (COX) staining demonstrating COX-negative muscle ﬁbers (bottom).Results
Histochemical analysis of muscle biopsy showed over
20% ragged-red ﬁbers (RRF) in skeletal-muscle biopsy of
the patient, with most ﬁbers being cytochrome c oxidase
(COX) negative (Fig. 1b). Fewer than 10% were RRF/
COX(+). Spectrophotometric measurement of respiratory
chain complexes in skeletal muscle showed that the residual
activities of NADH-ubiquinone oxidoreductase (complex
I) and cytochrome c oxidase (complex IV) were 46% and
23%, respectively, when referred to the activity of citrate
synthase, an index of mitochondrial mass.
Immunohistochemical staining of the patient’s muscle
using a speciﬁc antibody against a mtDNA-encoded sub-
unit of complex IV (COII) showed a mosaic pattern
whereas staining for complex II (Ip subunit), a nuclear-
DNA encoded subunit of complex IV (COIV) and complex
III (core 2) demonstrated normal patterns. Routine molec-
ular analyses identiﬁed no classic mutations, deletion or
duplication. However, a thorough investigation of the
tRNA genes identiﬁed a novel G>A transition at nucleo-
tide position 14724 (14724G>A) in tRNAGlu gene
(Fig. 2a and b). The mutation was nearly homoplasmic
(94%) in muscle and heteroplasmic (62%) in peripheral leu-
kocytes, it was absent in over 300 haplotype-matched con-
trol samples, and it alters a highly conserved nucleotide of
the tRNAGlu. The 14724G>A mutation was not found inial T2 weighted images demonstrated diﬀuse periventricular white matter
ichrome staining showing numerous ragged-red ﬁbres (top), cytochrome c
Fig. 2. Mutation analysis of the mitochondrial tRNAGlu gene. (a) Electropherogram of the polymerase chain reaction–ampliﬁed blood DNA of a control
(Ctrl) and of patient II-1; an arrow indicates the mutation. (b) Proposed tRNAGlu secondary structure showing the mutation at position 14724 in the DHU
stem (arrow). (c) Restriction fragment length polymorphism analysis of the 14724G>A mutation. M, patient skeletal muscle; B, patient blood; U, uncut;
L, DNA 100-bp ladder. The family pedigree is superimposed. (d) Quantiﬁcation of the 14724G>A mutation in the tRNAGlu in single muscle ﬁbers.
Cytochrome c oxidase-negative ﬁbres (COX): means ± SD 95.84 ± 1.21%; cytochrome c oxidase positive ﬁbres (COX+): 85.83 ± 2.71% (p < 0.01).
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and in two additional maternal relatives (Fig. 2c). Single
muscle ﬁber PCR analysis was performed to correlate levels
of abnormal mtDNA with the morphological phenotype.
The mean proportion of the mutant mtDNA in COX-
negative ﬁbers was 95.8 ± 1.2 (n = 20), and that in the
COX-positive ﬁbers was 85.8 ± 2.7 (n = 17). This ﬁnding
was signiﬁcant (p < 0.01) (Fig. 2d).
Discussion
In a 4-year-old child with encephalomyopathy, combi-
nation of clinical data with biochemical and morphological
impairment of oxidative metabolism strongly indicated a
defect in the mitochondrial genome. The presence of a mul-
tiple respiratory chain enzyme deﬁciency proposed an
impairment of the protein synthesis machinery within
mitochondria [15]. Accordingly, mtDNA sequence identi-
ﬁed a novel G>A point mutation at position 14724 in the
tRNAGlu gene.
In muscle tissue from the propositus, nearly 100% of the
mtDNA was mutated, whereas the mutational load wasonly 62% in blood. The mutation was absent in peripheral
leukocytes from the patient’s healthy mother and in three
additional asymptomatic maternal relatives. No other tis-
sue from the relatives was available for analysis leading
to the impression that the mutation originated de novo in
the germline of the developing embryo. No other change
of pathogenic signiﬁcance was identiﬁed when the mtDNA
sequences were compared to the revised consensus human
sequence [16].
The 14724G>A mutation is an additional disease-relat-
ed variant in the mitochondrial tRNAGlu gene. Although
some of the mitochondrial tRNA genes (e.g., tRNAIle,
tRNALeu(UUR) and tRNALys) are known to be mutational
hotspots, only four heteroplasmic mutations in the
tRNAGlu gene have been described, so far. Similar to other
mt-tRNA mutations the clinical spectrum of patients with
tRNAGlu mutations seems to be highly variable. The
14709T>C mutation in the anticodon-loop was identiﬁed
in several families with mitochondrial myopathy combined
with diabetes mellitus [17] whereas the 14696GA>G
change in the stem of the pseudouridine loop was recog-
nized in a Finnish patient with delayed psychomotor devel-
Fig. 3. Compilation of mammalian tRNAGlu genes. Nucleotide position 14724 (arrow) in the human gene is boxed. Alignment is based on the search of
common secondary structural domains and follows the structural characteristics included in Ref. [21].
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encephalomyopathy, lactic acidosis, and stroke-like epi-
sodes) syndrome [18]. On the other hand, the 14687T>C
variant in the TwC loop was detected in a sporadic child
with mitochondrial myopathy and respiratory distress
[19] while the 14739G>A mutation in the aminoacyl accep-
tor stem was recently reported in a girl with a predominant-
ly myopathic phenotype [20]. All presented an ample
heterogeneity in age of onset—which varied between birth
and the forth decade—mutation load (between 70% and
100%), and degree of CNS involvement. The mutation at
nt. 14724 lies at position 22 in the dihydrouridine (DHU)
stem of the tRNAGlu predicted secondary structure and is
distinctively associated with white and grey matter involve-
ment together with a skeletal myopathy. Diﬀerences in clin-
ical manifestations and severity of phenotype might only in
part be explained by location of the mutated nucleotide
within the tRNA predicted cloverleaf [21].
When one considers the consensus criteria for novel
pathogenic mt-tRNA variants [15,22], the 14724A>Gchange would score as ‘‘probably pathogenic’’ because of
indirect arguments. (1) No other mtDNA mutation or rear-
rangements were detected. (2) The mutation was absent in
a large set of haplotype-matched controls. (3) The involved
nucleotide within the tRNA displays high phylogenetic
conservation through evolution (Fig. 3). (4) The mutation
correlates well with the biochemical and morphological
defects in single muscle ﬁbers as shown by LCM-PCR anal-
yses. Unfortunately, no tissue was available to generate
transmitochondrial hybrids as to render ‘‘probably’’ more
certain.
The novel variant in mt-tRNAGlu gene aﬀects an
extremely conserved G”C bond in the DHU arm of the
tRNA predicted cloverleaf (Fig. 2b). As shown for another
pathogenic change aﬀecting the dihydrohuridine arm—
namely, the 3256C>T variant in the tRNALeu(UUR)
[23]—the mutation might well cause mitochondrial dys-
function by impairing mitochondrial protein synthesis.
For instance, this appears pertinent for ND6 and COII,
two mtDNA-encoded polypeptides with the maximum
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tions (www.mitomap.org). This might eventually explain
the combined complexes I and IV defect in the patient’s
muscle.
About 50% of the patients with white matter abnormal-
ities remain without diagnosis [24,25]. Mitochondrial
leukoencephalopathy [6] is not uncommon in the Kearns-
Sayre syndrome due to large-scale deletion of the mito-
chondrial genome but in childhood it mostly associates
with mutations in nDNA-encoded subunits of complex I
or, less frequently, with variants in SURF1 [26], which
encodes an ancillary protein required for correct COX
assembly. Moreover, mitochondrial leukodystrophy is
mandatory in patients with the MNGIE (myo-neuro-gas-
trointestinal encephalopathy) syndrome due to mutations
in TP. Thus, a speciﬁc protocol for studying and categoriz-
ing these patients should combine data concerning famil-
iarity, onset of symptoms, neurological examination,
presence of non-neurological symptoms, neurophysiologi-
cal studies as well as systematic neuroimaging [27]. MR
spectroscopy and new MR techniques will also provide
crucial information for deﬁning novel variants. In this
respect, our ﬁndings not only lend further evidence to the
expanding repertoire of mt-tRNA mutations in human dis-
eases but also propose that the ﬁnding of a leukoencepha-
lopathy of otherwise unclassiﬁed origin in a patient with a
complex neurologic picture and multisystem involvement
should prompt a thorough mitochondrial evaluation.
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